1. Home
  2. TTRX vs GSRF Comparison

TTRX vs GSRF Comparison

Compare TTRX & GSRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$9.77

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

GSRF

GSR IV Acquisition Corp. Class A ordinary share

SELL

Current Price

$10.30

Market Cap

302.0M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
TTRX
GSRF
Founded
2015
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
302.0M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
TTRX
GSRF
Price
$9.77
$10.30
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
83.5K
★ 111.6K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
N/A
P/E Ratio
★ N/A
$184.52
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$9.96
52 Week High
$16.45
$10.30

Technical Indicators

Market Signals
Indicator
TTRX
GSRF
Relative Strength Index (RSI) 43.98 79.27
Support Level $9.29 $10.15
Resistance Level $11.17 N/A
Average True Range (ATR) 0.94 0.01
MACD -0.02 -0.00
Stochastic Oscillator 49.55 100.00

Price Performance

Historical Comparison
TTRX
GSRF

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About GSRF GSR IV Acquisition Corp. Class A ordinary share

GSR IV Acquisition Corp is a blank check company.

Share on Social Networks: